Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UK-369,003 in Men with LUTS and Overactive Bladder
NCT00479505Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2007
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial of gisadenafil in overactive bladder (OAB) and lower urinary tract symptoms (LUTS) (2 arms), sponsored by Pfizer. Primary endpoint: Estimation Study with no primary endpoint at 12 Weeks. Started Jun 2007; status: completed.
02
Drugs
gisadenafil
03
Conditions
overactive bladder (OAB)lower urinary tract symptoms (LUTS)
Beyond the preview
Go deeper on NCT00479505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00479505.